Page last updated: 2024-12-06

gallein

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Gallein is a trihydroxyfluorone dye that was first synthesized in 1879. It is a reddish-brown solid that is soluble in water and alcohol. Gallein has been shown to have a variety of biological activities, including antioxidant, anti-inflammatory, and anticancer properties. It is also used as a pH indicator and as a mordant in dyeing. Gallein is studied for its potential therapeutic applications, particularly in the treatment of cancer and inflammatory diseases.'

gallein: do not confuse with gallin; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

gallein : A xanthene dye that is fluoran carrying four hydroxy substituents at positions 3', 4', 5' and 6'. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID73685
CHEMBL ID4469620
CHEBI ID88294
SCHEMBL ID334144
MeSH IDM0051240

Synonyms (63)

Synonym
alizarin violet
nsc622478
mordant violet 25
nsc-622478
gallein
c.i. mordant violet 25
4,5-dihydroxyfluorescein
nsc8668
fluoran,4',5',6'-tetrahydroxy-
nsc-8668
2103-64-2
c.i. 45445
spiro[isobenzofuran-1(3h), 3',4',5',6'-tetrahydroxy-
fluorescein,5'-dihydroxy-
pyrogallolphthalein
52413-17-9
spiro[isobenzofuran-1(3h),9'-[9h]xanthen]-3-one, 3',4',5',6'-tetrahydroxy-
pyrogallolphthalein: 12,13,14,15-tetrahydroxyspiro[3-hydroisobenzofuran-3,9'-xanthene]-1-one
3',4',5',6'-tetrahydroxyspiro[isobenzofuran-3,9'-xanthene]-1-one
nsc56445
nsc-56445
A0601
3',4',5',6'-tetrahydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one
pyrogallol phthalein
callein
einecs 218-272-6
8l0084u2qr ,
fluorescein, 4',5'-dihydroxy-
fluoran, 3',4',5',6'-tetrahydroxy-
3',4',5',6'-tetrahydroxyspiro(isobenzofuran-1(3h),9'-(9h)xanthene)-3-one
spiro(isobenzofuran-1(3),9'-(9h)xanthen)-3-one, 3',4',5',6'-tetrahydroxy-
nsc 56445
3',4',5',6'-tetrahydroxyfluoran
nsc 622478
spiro(isobenzofuran-1(3h),9'-(9h)xanthen)-3-one, 3',4',5',6'-tetrahydroxy-
ai3-63042
nsc 8668
unii-8l0084u2qr
FT-0603588
AKOS015903075
S5978
SCHEMBL334144
3',4',5',6'-tetrahydroxy-3h-spiro[isobenzofuran-1,9'-xanthen]-3-one
DTXSID5062180
W-107581
3',4',5',6'-tetrahydroxyspiro[isobenzofuran-1(3h),9'-(9h)xanthen]-3-one
gallein [mi]
c.i.- 45445
3',4',5',6'-tetrahydroxy-3h-spiro[2-benzofuran-1,9'-xanthen]-3-one
CHEBI:88294
alizarine violet
PHLYOKFVXIVOJC-UHFFFAOYSA-N
mfcd00041839
3',4',5',6'-tetrahydroxyspiro[isobenzofuran-1(3h),9'-[9h]xanthene]-3-one
CHEMBL4469620 ,
CS-0010160
HY-D0254
Q2119993
D88292
gallein( pyrogallol phthalein )
bdbm50514448
AS-75768
CAA10364

Research Excerpts

Treatment

Gallein treatment significantly reduced (P < 0.05) the number of proliferating cell nuclear antigen-positive tubular epithelial cells at 24 hours after the ischemia-reperfusion phase in vivo. Gallein pretreatment also prevented acute antinociceptive tolerance induced by morphine.

ExcerptReferenceRelevance
"Gallein pretreatment also prevented acute antinociceptive tolerance induced by morphine."( Inhibition of Gβγ-subunit signaling potentiates morphine-induced antinociception but not respiratory depression, constipation, locomotion, and reward.
Bidlack, JM; Carey, AN; Hoot, MR; McLaughlin, JP; Reilley, KJ; Sypek, EI, 2013
)
1.11
"Gallein treatment significantly reduced (P < 0.05) the number of proliferating cell nuclear antigen-positive tubular epithelial cells at 24 hours after the ischemia-reperfusion phase in vivo."( G-protein βγ subunit dimers modulate kidney repair after ischemia-reperfusion injury in rats.
Goldberg, M; Haines, E; North, LM; Park, F; Pressly, JD; Regner, KR; Sullivan, LM; Weber, DS; White, SM, 2014
)
1.12
"Pretreatment with gallein produced a dose-dependent potentiation of morphine-mediated antinociception, producing up to a 10-fold leftward shift in the morphine dose-response curve and extending the duration of antinociception induced by a single dose of morphine."( Inhibition of Gβγ-subunit signaling potentiates morphine-induced antinociception but not respiratory depression, constipation, locomotion, and reward.
Bidlack, JM; Carey, AN; Hoot, MR; McLaughlin, JP; Reilley, KJ; Sypek, EI, 2013
)
0.71

Dosage Studied

ExcerptRelevanceReference
" Pretreatment with gallein produced a dose-dependent potentiation of morphine-mediated antinociception, producing up to a 10-fold leftward shift in the morphine dose-response curve and extending the duration of antinociception induced by a single dose of morphine."( Inhibition of Gβγ-subunit signaling potentiates morphine-induced antinociception but not respiratory depression, constipation, locomotion, and reward.
Bidlack, JM; Carey, AN; Hoot, MR; McLaughlin, JP; Reilley, KJ; Sypek, EI, 2013
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
fluorochromeA fluorescent dye used to stain biological specimens.
histological dyeA dye used in microscopic or electron microscopic examination of cells and tissues to give contrast and to highlight particular features of interest, such as nuclei and cytoplasm.
G-protein-coupled receptor antagonistAn antagonist at G-protein-coupled receptor.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
gamma-lactoneA lactone having a five-membered lactone ring.
polyphenolMembers of the class of phenols that contain 2 or more benzene rings each of which is substituted by at least one hydroxy group.
xanthene dyeA dye derived by condensation of phthalic anhydride with resorcinol (and derivatives) or m-aminophenol (and derivatives).
oxaspiro compoundA spiro compound in which at least one of the cyclic components is an oxygen heterocyle.
organic heteropentacyclic compound
2-benzofurans
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2Homo sapiens (human)IC50 (µMol)0.20000.20005.066710.0000AID1559772
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)IC50 (µMol)0.20000.20005.066710.0000AID1559772
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (12)

Processvia Protein(s)Taxonomy
adenylate cyclase-activating dopamine receptor signaling pathwayGuanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2Homo sapiens (human)
fibroblast proliferationGuanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2Homo sapiens (human)
cellular response to prostaglandin E stimulusGuanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2Homo sapiens (human)
cellular response to catecholamine stimulusGuanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2Homo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2Homo sapiens (human)
signal transductionGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
Ras protein signal transductionGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
cell population proliferationGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
sensory perception of tasteGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
retina development in camera-type eyeGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
cellular response to prostaglandin E stimulusGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
cellular response to catecholamine stimulusGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
protein bindingGuanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2Homo sapiens (human)
G-protein beta-subunit bindingGuanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2Homo sapiens (human)
GTPase activityGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
protein bindingGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
protein-containing complex bindingGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
GTPase bindingGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
signaling receptor complex adaptor activityGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2Homo sapiens (human)
membraneGuanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2Homo sapiens (human)
extracellular exosomeGuanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2Homo sapiens (human)
heterotrimeric G-protein complexGuanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2Homo sapiens (human)
lysosomal membraneGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
cytosolGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
plasma membraneGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
membraneGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
synapseGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
extracellular exosomeGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
photoreceptor disc membraneGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
extracellular vesicleGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
heterotrimeric G-protein complexGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
cytoplasmGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1559772Inhibition of G-protein beta1gamma2 (unknown origin) by flow cytometry2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Heterotrimeric G Proteins as Therapeutic Targets in Drug Discovery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (44)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (2.27)18.7374
1990's0 (0.00)18.2507
2000's8 (18.18)29.6817
2010's30 (68.18)24.3611
2020's5 (11.36)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 60.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index60.52 (24.57)
Research Supply Index3.81 (2.92)
Research Growth Index4.83 (4.65)
Search Engine Demand Index98.99 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (60.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.27%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other43 (97.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]